

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 1 of 1	ATTY. DOCKET NO.	SERIAL NO.
	0269.01/C	10/652,814
	APPLICANT	
	Unger	
FILING DATE	GROUP	
August 29, 2003	1633	

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	C L S	SUB- CLS	FILE DATE
AA		6,489,458	12/3/2002	HACKETT, ET AL.			
AB		US 2003/087323	10/23/2009	UNGER			
AC		US 2004/0038303	2/26/2004	UNGER			
AD		US 2004/0038406	2/26/2004	UNGER			
AE		US 2008/0113932 A1	05/15/2008	SLATON, ET AL.			
AF		US 2008/0220072 A1	09/11/2008	UNGER, ET AL.			
AG		US 2009/0238883	9/24/2009	KREN, ET AL.			

FOREIGN PATENT DOCUMENTS						
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS
AH		WO 08/095192	8/7/2008	PCT		
AI		WO 08/157514	12/24/2008	PCT		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
AJ	Cook (1998) Antisense Medicinal Chemistry, Springer, New York, pp.51-101.
AK	Dresser, MJ (2001) "The MDR1 C3425T polymorphism: effects on P-glycoprotein expression/function and clinical significance," AAPS PharmSci, 3(23):3, Clinical Pharmacology
AL	Handbook of Pharmaceutical Excipients, (Arthur H. Kibbe, Ph.D., ed. American Pharmaceutical Association 2000) (1986)
AM	Halin et al., (2002) "Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature," Nature Biotech 20:264-269.
AN	Heidel, Jeremy et al., (2005) "Molecular Conjugates," Adv. Biochem. Engin./Biotechnol: 99, 7-39.
AO	Kong, Garheng et al., (2000) "Hyperthermia Enables Tumor-specific Nanoparticle Delivery: Effect of Particle Size," Cancer Research, 60:4440-4445.
AP	Nagano et al., "Extracellular matrix modulates the proliferation of rat astrocytes in serum-free culture," Glia, 8:71-76
AQ	Schneider, Holm et al., (1999) "Targeted gene delivery into $\alpha_5\beta_1$ -integrin-displaying cells by a synthetic peptide," FEBS Letters, 458:329-332.
AR	Smith, James G. and Ho, Isaac, (1972) "The Reductive Dimerization of Schiff Bases by Alkali Metals. Isomerization of the Dimeric Dianions," Journal of Organic Chemistry, 37(4):653-656.
AS	S.T. CROOKE, Chapter 1: Basic Principles on Antisense Therapeutics pp. 1-50.
AT	Summerton and Weller (1997) Antisense Nuc. Acid Drug Devel. 7:187-195.
EXAMINER _____ DATE CONSIDERED _____	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 2 of 2	ATTY. DOCKET NO.	SERIAL NO.
	0269.01/C	10/652,814
	APPLICANT	
	Unger	
	FILING DATE	GROUP
	August 29, 2003	1633

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB-CLS	FILE DATE
	AU						
	AV						
	AW						
	AX						
	AY						
	AZ						
	AAA						
	ABB						
	ACC						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	BA						
	BB						
	BC						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
	BD	Wang (2006) "CK2 Signaling in androgen-dependent and independent prostate cancer" J. Cell Biochem. 99(2):382-391.		
	BE	Wong (1991) "Chemistry of Protein Conjugation and Cross-Linking" CRC Press		
	BF	Yamamoto et al., (1999) "Induction of Tenascin-C in Cardiac Myocytes by Mechanical Deformation," J. Biol. Chem. 274(31):21840-21846.		
	BG	Yuan et al., (1994) "Microvascular Permeability and Interstitial Penetration of Sterically Stabilized (Stealth) Liposomes in a Human Tumor Xenograft" Cancer Research 54:3352-3356.		
	BH	Zhang et al., (1997) "Comparision of Integrins in Human Skin, Pig Skin, and Perfused Skin: An In Vitro Skin Toxicology Model" Journal of Applied Toxicology 17(4):247-253		
EXAMINER	/Ileana Popa/		DATE CONSIDERED	05/27/2010
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and <u>not</u> considered. Include copy of this form with next communication to applicant.				